|
| 36226489 | Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy. | Haematologica | 2023 |
| 36888611 | Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. | PLoS One | 2023 |
| 36865133 | The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases. | Res Sq | 2023 |
| 36563938 | A protracted outbreak of difficult-to-treat resistant Pseudomonas aeruginosa in a haematology unit: a matched case-control study demonstrating increased risk with use of fluoroquinolone. | J Hosp Infect | 2023 |
| 34843717 | Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα. | Biochem Pharmacol | 2022 |
| 35499387 | Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia. | Mol Cancer Ther | 2022 |
| 34381596 | Conformational fingerprinting of tau variants and strains by Raman spectroscopy. | RSC Adv | 2021 |
| 29626126 | APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. | Mol Cancer Ther | 2018 |
| 29626127 | APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells. | Mol Cancer Ther | 2018 |
| 22169261 | Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs. | Bioorg Med Chem Lett | 2012 |
| 24900516 | Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. | ACS Med Chem Lett | 2012 |
| 22789538 | Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. | Cancer Cell | 2012 |
| 22460033 | Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. | Bioorg Med Chem Lett | 2012 |
| 22267551 | CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. | Mol Cancer Ther | 2012 |
| 22387988 | Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. | Cancer Lett | 2012 |
| 21159662 | Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. | Cancer Res | 2011 |
| 24900437 | Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor. | ACS Med Chem Lett | 2011 |
| 22027148 | Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. | Biochem Biophys Res Commun | 2011 |
| 21755459 | Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. | Mol Cell Biochem | 2011 |
| 21316963 | Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties. | Bioorg Med Chem Lett | 2011 |
| 21174434 | Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. | J Med Chem | 2011 |
| 20055700 | The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. | Annu Rev Pharmacol Toxicol | 2010 |
| 21159648 | CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. | Cancer Res | 2010 |
| 19738048 | Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. | Cancer Res | 2009 |
| 12818684 | Synthesis, resolution, and determination of the absolute configuration of the enantiomers of cis-4,5-dihydroxy-1,2-dithiane 1,1-dioxide, an HIV-1NCp7 inhibitor. | Bioorg Med Chem | 2003 |
| 12639244 | In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model. | AIDS Res Hum Retroviruses | 2003 |
| 11858998 | Benzamide-based thiolcarbamates: a new class of HIV-1 NCp7 inhibitors. | Bioorg Med Chem Lett | 2002 |
| 11886789 | Synthesis and biological properties of amino acid amide ligand-based pyridinioalkanoyl thioesters as anti-HIV agents. | Bioorg Med Chem | 2002 |
| 11325274 | The secondary amine/nitric oxide complex ion R(2)N[N(O)NO](-) as nucleophile and leaving group in S9N)Ar reactions. | J Org Chem | 2001 |
| 10809733 | Inactivation of HIV-1 nucleocapsid protein P7 by pyridinioalkanoyl thioesters. Characterization of reaction products and proposed mechanism of action. | J Biol Chem | 2000 |
| 10574965 | Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions. | J Biol Chem | 1999 |
| 10413422 | Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. | J Natl Cancer Inst | 1999 |
| 10346929 | Extension of the polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency. | J Med Chem | 1999 |
| 10212126 | Chicoric acid analogues as HIV-1 integrase inhibitors. | J Med Chem | 1999 |
| 10464020 | Thiazolothiazepine inhibitors of HIV-1 integrase. | J Med Chem | 1999 |
| 9888834 | Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. | J Med Chem | 1999 |
| 9751708 | Reactivity of the HIV-1 nucleocapsid protein p7 zinc finger domains from the perspective of density-functional theory. | Proc Natl Acad Sci U S A | 1998 |
| 9871653 | Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index. | Bioorg Med Chem Lett | 1998 |
| 9871550 | Synthesis of a cosalane analog with an extended polyanionic pharmacophore conferring enhanced potency as an anti-HIV agent. | Bioorg Med Chem Lett | 1998 |
| 9665268 | Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. | J Leukoc Biol | 1998 |
| 9517921 | Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. | Antimicrob Agents Chemother | 1998 |
| 9554870 | Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. | J Med Chem | 1998 |
| 9632350 | Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. | J Med Chem | 1998 |
| 9624499 | Efficacies of zinc-finger-active drugs against Giardia lamblia. | Antimicrob Agents Chemother | 1998 |
| 9622549 | New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors. | J Med Chem | 1998 |
| 9055865 | Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. | Nat Med | 1997 |
| 9209313 | Suppression of retrovirial replication: inactivation of murine leukemia virus by compounds reacting with the zinc finger in the viral nucleocapsid protein. | Leukemia | 1997 |
| 9113335 | A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: the 2,2'-dithiobisbenzamides. | Bioorg Med Chem | 1997 |
| 9207937 | Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS. | J Med Chem | 1997 |
| 9144524 | Differential infection of CD34+ cell-derived dendritic cells and monocytes with lymphocyte-tropic and monocyte-tropic HIV-1 strains. | J Immunol | 1997 |